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 Millions of genomes, exomes, transcriptomes over the last decades 
 Validated mainly on high quality DNA or FFPE samples, some papers on DBS 
reporting only technical capacities  
 Filter paper 
 Evolved as a reference procedure for collection, transport, analysis and storage of 
biological fluids (ie CLSI guidelines) 
 Applications : NBS, diet follow-up, TDM and doping control, viral load measurements, 
targeted genes sequencing,… 
 
 Objectives 
 Evaluate WES on DBS material – 15 IEM patients 
 Quality and quantity of retrieved DNA 
 Detection of known mutation 






Framework for variation discovery 
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Studied genes 
 35 IEM genes considered 
by NBS program in 
Wallonia 
 
 65 genes considered by 
diverse NBS programs 
worldwide 
A. IEM currently screened in FWB Genes B. Disorders considered by different NBS 
programs or initiatives worldwide 
Genes 
Phenylketonuria PAH Cystic Fibrosis CFTR 
Phenylketonuria PTS Congenital Adrenal Hyperplasia CYP21A2 
Phenylketonuria GCH1 Biotinidase deficiency BTD 
Phenylketonuria QDPR 3-Methylcrotonyl-CoA Carboxylase MCCC2 
Phenylketonuria PCBD1 Hemoglobin disorders HBB 
MSUD DBT Hemoglobin disorders HBA1 
MSUD BCKDHA Hemoglobin disorders HBA2 
MSUD BCKDHB G6PD deficiency G6PD 
Tyrosinemia FAH Alpha1-Antitrypsin deficiency SERPINA1 
Tyrosinemia TAT Duchenne-Becker dystrophy DMD 
Tyrosinemia HPD Hurler disease IDUA 
Homocystinuria CBS Hunter disease IDS 
Homocystinuria MTHFR Morquio disease GALNS 
Homocystinuria MTRR Maroteaux-Lamy syndrome ARSB 
Homocystinuria MTR Gaucher disease BGBA 
Galactosemia GALT Niemann–Pick A/B disease SMPD1 
Galactosemia GALK1 Pompe disease GAA 
Galactosemia GALE Krabbe disease GALC 
Methylmalonic Acidemia MUT Fabry disease GLA 
Methylmalonic Acidemia MMACHC X-Adrenoleukodystrophy ABCD1 
Methylmalonic Acidemia MMADHC Severe Combined Immunodeficiency IL2RG 
Methylmalonic Acidemia LMBRD1 Severe Combined Immunodeficiency JAK3 
Methylmalonic Acidemia HCFC1 Severe Combined Immunodeficiency IL7RA 
Methylmalonic Acidemia MMAA Severe Combined Immunodeficiency IL2RA 
Methylmalonic Acidemia MMAB Severe Combined Immunodeficiency PTPRC 
Methylmalonic Acidemia TCN2 Severe Combined Immunodeficiency CD3D 
Propionic Acidemia PCCA Severe Combined Immunodeficiency CD3E 
Propionic Acidemia PCCB Severe Combined Immunodeficiency CD3Z 
Glutaric Aciduria type I GCDH Severe Combined Immunodeficiency CORO1A 
Isovaleric Acidemia IVD Severe Combined Immunodeficiency RAG1 
MCAD ACADM Severe Combined Immunodeficiency RAG2 
MADD ETFDH Severe Combined Immunodeficiency DCLRE1C 
MADD ETFA Severe Combined Immunodeficiency PRKDC 
MADD ETFB Severe Combined Immunodeficiency AK2 
VLCAD ACADVL Severe Combined Immunodeficiency ADA 
  Severe Combined Immunodeficiency LIG4 
  Severe Combined Immunodeficiency NHEJ1 
  Severe Combined Immunodeficiency CD3G 
  Severe Combined Immunodeficiency CD8A 
  Severe Combined Immunodeficiency PNP 
  Severe Combined Immunodeficiency RMRP 
  Severe Combined Immunodeficiency ZAP70 
  Severe Combined Immunodeficiency CD40LG 
  Severe Combined Immunodeficiency FOXP3 
  Severe Combined Immunodeficiency IL10RA 
  Congenital Hypothyroidism
a
 TSHR 
  Congenital Hypothyroidism
a THRA 
  Congenital Hypothyroidism
a THRB 
  Congenital Hypothyroidism
a FOXE1 
  Congenital Hypothyroidism
a NKX2-1 
  Congenital Hypothyroidism
a NKX2-5 
  Congenital Hypothyroidism
a PAX8 
  Congenital Hypothyroidism
a SLC26A4 
  Congenital Hypothyroidism
a FOXI1 
  Congenital Hypothyroidism
a KAT6B 
  Congenital Hypothyroidism
a KCNJ10 
  Congenital Hypothyroidism
a UBR1 
  Congenital Hypothyroidism
a GNAS 
  Congenital Hypothyroidism
a SLC16A2 
  Congenital Hypothyroidism
a TPO 
  Congenital Hypothyroidism
a SLC5A5 
  Congenital Hypothyroidism
a DUOX2 
  Congenital Hypothyroidism
a DUOXA2 
  Congenital Hypothyroidism
a IYD 




Molecular aetiology of Congenital Hypothyroidism (CH) is not fully understood yet. Only genes currently known 
as defective in CH are reported. 
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Coverage depth for the different exons 
 35 IEM genes included in the 
ONE NBS program 
 65 genes considered by 
different NBS programs 
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Identification of known  
mutations 
 All mutations readily detected by WES but 
 
 DBS-14 (~10 years old) : MSUD 
 Xle = 1262 µmol/L @NBS, AA : allo-Ile => MSUD 
 Sanger seq. pending 
 WES : no causing mutations in DBT, BCKDHA, or BCKDHB genes 
  Could not exclude DBT large deletion although coverage is not statistically different 
 from the other 14 samples analyzed  
  => Intronic causal mutation ? 
 DBS-12 : GALT 
 4 base-pairs deletion located in the promoter region of Duarte 2 haplotype not covered by 
our probes 
 DBS-5 : MMA 
 Identification of 15 base-pairs duplication in MMAB gene was critical : not annotated by 
ANNOVAR, neither automatically identified with IGV soft 
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“Presumed benign” polymorphisms?  
 Number of variants (in 100 genes) annotated in the different samples, 
and the putative clinical relevance of filtered polymorphism evaluated with 










 Pathogenic Unknown Benign VUS
b
 Pathogenic Unknown 
DBS-1 336 10 0 3 1 6 4 1 2 3 
DBS-2 276 9 0 3 1 5 3 0 1 5 
DBS-3 317 7 0 1 0 6 3 1 1 2 
DBS-4 432 18 0 10 0 8 6 1 1 10 
DBS-5 342 9 0 2 1 6 3 0 1 5 
DBS-6 339 9 0 3 1
c
 5 5 0 2
c
 2 
DBS-7 335 10 0 2 2 6 4 1 2 3 
DBS-8 338 10 0 5 1 4 3 2 1 4 
DBS-9 429 10 0 3 0 7 3 0 1 6 
DBS-10 336 16 1 8 1 6 9 0 2 5 
DBS-11 296 6 0 3 0 3 2 1 0 3 
DBS-12 350 5 0 0 1 4 2 0 1 2 
DBS-13 353 9 0 2 0 7 4 2 0 3 
DBS-14 337 8 0 5 0 3 4 2 0 2 
DBS-15 337 10 0 3 0 7 3 2 1 4 
a 
Filtering criteria’s: frequency < 1%, located in exon or splicing site (within the first 8 intronic nucleotides), non-synonymous 
b 
Variant of Unknown Significance 
c 
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“Presumed benign” polymorphisms?  
 DBS-6 with TYR I : causal homozygote mutation c.554-1G>T in FAH 
 + Identification of pathogenic nonsense homozygote mutation c.2056C>T 
(p.Gln686Ter) in DUOX2 gene (coverage 6x) => known to cause thyroid 
dyshormonogenesis type 6 and CH.  
 24 years old patient with fully normal thyroid function (repeated normal 
thyroxin and thyrotropin over years).  
 Confirmation on 2nd experiment (coverage 27x) + Sanger sequencing  
 How to explain Genotype/Phenotype discrepancy for a truncated protein? 
 Mutation located downstream of the Thyroperoxidase active site. 
 Variant databases rely on an unique NEJM publication, reporting a single 
heterozygote patient. No functional studies  
 => Should this variant be classified as probably benign?? 
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Analytical conclusions 
 Amount and quality of DNA extracted from DBS are adequate to identify 
pathogenic mutations by high throughput sequencing 
 
 WES reveals large depth of coverage fluctuations between regions, what 
could subsequently generate difficulties in variant interpretation.  
 Detection of CNV is also subject to caution as unambiguous identification 
of small or large allelic deletions by NGS can be challenging when the 
coverage is poor. Moreover, as observed with the 15 base-pairs 
duplication in the MMAB gene, small CNV’s are not easily identified by 
bioinformatics tools.  
 Unexpected homozygote pathogen mutation has additionally been 
characterized in genes unrelated to patient’s disorder, questioning the 
reliability of some variants referenced in databases.  
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Ready for Next Gen NBS? 
 1st revolution in NBS : introduction of MS 15 years ago. 
 2nd revolution underway : NGS as universal approach allowing identification of any 
disorders with one sole technology.  
 Costs 
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Ready for Next Gen NBS? 
 1st revolution in NBS : introduction of MS 15 years ago. 
 2nd revolution underway : NGS as universal approach allowing identification of any 
disorders with one sole technology.  
 Costs 
 Poor predictive value (heterozygous carriers, polymorphisms and intermediate deficiencies) 
=> heavy impacts on medical practices and health care budgets. 
 Clarification of genotype/phenotype correlations required => Improvement of genomic 
knowledge and subsequent enhancement of sensitivity and specificity.  
 WES generates very large amount of additional data (fastidious bioinformatics treatment 
and variant’s reviewing) => high TAT. 
 => Implementation of targeted approach (to easier the coverage homogenization with 
minimal read depth threshold), apparition of consolidated bioinformatics flowchart  
 => Reduction of NGS analysis time.  
 List of target genes not to be restrictive, as NBS programs are constantly evolving with new 
therapies dvpt.  
 Earlier blood collection (day of birth, cord blood ?) => anticipation of medical care? 
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Ready for Next Gen NBS? 
 Voluntary expansion of screening providing choice to families who want to know about 
other conditions?  
 Current restriction to diseases with effective treatment ignores potential benefits of any 
preventive intervention.  
 Early identification of patients for other conditions could probably allow assessing pre-
symptomatic therapies in randomized studies.  
 Huge educational challenges 
 Health professionals training and public information 
 Parents should be entitled to be informed of the results, of its implications and of the 
follow-up required.  
 Appropriate infrastructures, education, follow-up and psychological assistance should be 
set up. 
 Specific registries to be created.  
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Ready for Next Gen NBS? 
 
 
 “Next-Generation” NBS is underway 
New era questioning the current neonatal screening dogmas 
 
New paradigms have to be agreed 
 Clinical, political, economical, societal and ethical debates  
 “Science without conscience is only ruin of the soul” 
